Findings

What do systematic reviews say?

3 questions · 3 findings · 1 reviews

Sort:Best matchNewest Highest certainty Download CSV

No studies found 0 · 0%GRADE not reported 0 · 0%Very low 0 · 0%Low 0 · 0%Moderate 2 · 66.7%High 1 · 33.3%

Group 1 Pulmonary arterial hypertension ‐ PDE5i vs placebo

Improvement in WHO functional class · pulmonary arterial hypertension

Group 1 Pulmonary arterial hypertension ‐ PDE5i leads to higher improvement in WHO functional class compared with placebo (high certainty).

1 finding from 1 review

Phosphodiesterase 5 inhibitors for pulmonary hypertension 2019 · Cochrane Headline outcomes only
OR 8.59 [3.95, 18.72]
4 studies · 282 participants
High

Group 1 Pulmonary arterial hypertension ‐ PDE5i vs ERA

Improvement in WHO functional class · pulmonary arterial hypertension

Group 1 Pulmonary arterial hypertension ‐ PDE5i showed no clear difference in improvement in WHO functional class compared with ERA (moderate certainty).

1 finding from 1 review

Phosphodiesterase 5 inhibitors for pulmonary hypertension 2019 · Cochrane Headline outcomes only
OR 0.94 [0.55, 1.6]
1 study · 244 participants
Moderate

Group 1 Pulmonary arterial hypertension ‐ PDE5i vs placebo, on combination therapy

Improvement in WHO functional class · pulmonary arterial hypertension

Group 1 Pulmonary arterial hypertension ‐ PDE5i showed no clear difference in improvement in WHO functional class compared with placebo, on combination therapy (moderate certainty).

1 finding from 1 review

Phosphodiesterase 5 inhibitors for pulmonary hypertension 2019 · Cochrane Headline outcomes only
OR 1.2 [0.66, 2.17]
2 studies · 227 participants
Moderate